NCT06075134 EMG-guided Botox Injection Versus Conventional Botox Injection in Gummy Smile Patients
| NCT ID | NCT06075134 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Excessive Gingival Display |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 32 participants in total. It began in 2024-11-01 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare the effect of EMG-guided Botox injection with conventional Botox injection in Yonsei point, in patients with excessive gingival display. The main question it aims to answer is: • Does the use of electromyography (EMG) as a guide during Botox injection for patients with gummy smile has better effect than conventional injection in Yonsei point? Participants will be randomized in equal proportions between intervention and control groups. * Preoperative assessment of amount of gingival display, lip length (philtrum and vermilion length), and smile type. * For the intervention group, EMG readings will be done in Clinical Neurophysiology Department, Kasr Al-Ainy Hospital EMG-guided Botox injection (Intervention group). Conventional Botox injection in Yonsei point (Control group).
Eligibility Criteria
Inclusion Criteria: * Patients with excessive gingival display. * Patients with esthetic concerns. * Patients with mild to moderate VME (vertical maxillary excess). * Normal clinical crown dimensions. * Patients aged 18 to 50. * Systemically healthy patients. * Non-smokers. Exclusion Criteria: * Patients with severe VME (vertical maxillary excess). * Pregnant and breastfeeding women. * Patients with gingival inflammation and/or enlargement. * Inflammation or infection at the site of injection. * Patients with known allergy to any of the components of Botox (i.e., saline, human albumin, lactose and sodium succinate). * Patients using anticholinesterase or other agents affecting neuromuscular transmission. * Psychologically unstable patients or those who have unrealistic expectations and questionable motives. * Patients with neuromuscular disorders (e.g., myasthenia gravis, Eaton-Lambert syndrome).
Contact & Investigator
Sherry Fayez Akhnokh, BSc
PRINCIPAL INVESTIGATOR
Cairo University
Frequently Asked Questions
Who can join the NCT06075134 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Excessive Gingival Display. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06075134 currently recruiting?
Yes, NCT06075134 is actively recruiting participants. Contact the research team at sherry.akhnokh@dentistry.cu.edu.eg for enrollment information.
Where is the NCT06075134 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06075134 clinical trial?
NCT06075134 is sponsored by Cairo University. The principal investigator is Sherry Fayez Akhnokh, BSc at Cairo University. The trial plans to enroll 32 participants.